Giuseppe Mazza | BiotechTV

top of page

GSK and London based Engitix Therapeutics announced today they will collaborate on first in class targets for liver fibrosis regression using Engitix's extracellular matrix (ECM) discovery platform

GSK will pay Engitix approximately $59M up front and up to approximately $157M more in potential milestones. Engitix Co-Founder and CEO Giuseppe Mazza discusses the deal and the company's platform.

Company News

2 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

GSK and London based Engitix Therapeutics announced today they will collaborate on first in class targets for liver fibrosis regression using Engitix's extracellular matrix (ECM) discovery platform

Follow BiotechTV

Sponsors

Sponsor Spotlight